---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019393"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T12:25:51.391983+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech enters research agreement with Japan's NIID to study Ampligen's effect on viral shedding

## Summary
- Agreement with Japanese National Institute of Infectious Disease to evaluate Ampligen's capacity to prevent viral shedding in respiratory virus infections.
- AIM supplies Ampligen free of charge; NIID conducts research; quarterly oral updates and final written report within 60 days.
- Intellectual property ownership follows US inventorship law; no automatic license granted to NIID.
- Agreement terminates upon completion, written agreement, or one year from effective date (May 8, 2023).

## SEC filing metadata
- accession: 0001493152-23-019393
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/0001493152-23-019393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019393
- JSON: https://secwatch.observer/filing/0001493152-23-019393.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019393.txt

## Key facts
- Material Agreements
  AIM ImmunoTech Inc. entered into Material Transfer and Research Agreement with Japanese National Institute of Infectious Disease (effective 2023-05-22).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Japanese National Institute of Infectious Disease
  - Effective: 2023-05-22
  source text: On May 22, 2023, AIM ImmunoTech Inc. (the “Company”) and the Japanese National Institute of Infectious Disease (the “JNIID”) entered into a Material Transfer and Research Agreement (the “Agreement).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/0001493152-23-019393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.